Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 750

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 7
Chunk 750
---
 therapeutics is efficient integration of complex
and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial
intelligence and machine learning (“AI/ML”) has emerged as a digital solution to help address this problem.

The
Company uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current
AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. The Company’s
analytical platform is composed of an ensemble of state-of-the-art machine learning and artificial intelligence models. The Company’s
core platform technology, named bfLEAP™, is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics
Laboratory (JHU-APL) which we believe is able to surmount the challenges of scalability and flexibility currently hindering researchers
and clinicians by providing a more precise, multi-dimensional understanding of their data. The Company is deploying its analytical platform,
including bfLEAP™, for use in several critical stages of development of internal programs and through strategic partnerships and
collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs
by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies
they need.

The
proprietary analytical platform utilizes both supervised and unsupervised machine learning. As such, it is able to reveal real and meaningful
connections in the data without the need for a priori hypothesis. Algorithms used in the platform are designed to handle highly imbalanced
data sets and successfully identify combinations of factors that are associated with outcomes of interest. The Company’s platform
leverages models that use both correlative and causative machine learning and artificial intelligence approaches which provide a comprehensive
approach to predictive analysis which is expected to lead to meaningful insights including the molecular drivers of disease. In this
regard, with the Company’s access to proprietary data sets such as its strategic data and commercialization agreements with the
Lieber Institute for Brain Development (“LIBD”), the Company has increased its internal efforts on target discovery.

The
Company’s goal is to improve the odds of success at all stages of pre-clinical and clinical therapeutics development for in-house
programs and for its strategic partners and collaborators. The Company’s business model includes enabling the success of ongoing
clinical trials and rescuing late stage failed drugs (i.e., Phase II or Phase III clinical trial failures) by bringing them